Acute Myeloid Leukemia
We recommend
New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy
Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.
Maintenance Therapy of a Female Patient with AML After Intense Chemotherapy – Case Study
The following case study presents the case of a female patient with acute myeloid leukemia (AML)…
Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy
The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs…
Articles on this topic
Picking from the Red Book of the CHS: What's New in This Year's Recommendations for Diagnosis and Treatment of AML?
In recent years, there have been significant advances in the diagnosis and therapy of acute…
Oral Azacitidine After Achieving Remission in AML Improves Survival and Does Not Worsen Quality of Life
Orally administered azacitidine as maintenance therapy in patients with acute myeloid leukemia…
INFOGRAPHIC: Post-Induction Therapy for AML – Current Guidelines
What are the recommended therapeutic modalities for consolidation and maintenance therapy of…
Management of Adverse Effects During Maintenance Treatment of AML Patients
The randomized phase III study QUAZAR AML-001 evaluated the maintenance treatment of acute…
Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
The work cited below presents freshly updated results from the Quazar AML-001 study evaluating…
Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease
Intensive chemotherapy for patients newly diagnosed with acute myeloid leukemia (AML) often…
Prognostic Significance of Mutations in Maintenance Hypomethylation Therapy for AML Patients
A recently published sub-analysis of the QUAZAR AML-001 clinical trial evaluated the efficacy…
Current Recommendations by the ELN Expert Panel on AML Diagnosis Management
The 2022 recommendations from European LeukemiaNet (ELN) add new information to the previous…
Current Position of Venetoclax in the Treatment of AML − Hope for a Better Prognosis?
The treatment of acute myeloid leukemia (AML) remained stagnant for a long time, with many new…
Journal articles Novel molecules used in the targeted treatment of acute myeloid leukaemia – adverse reactions, treatment complications and signifi cant drug interactions
Ač je akutní myeloidní leukemie onemocnění s rostoucí incidencí, v posledních desetiletích nedošlo...
1
2
Subscribe
Most read on this topic
Related topic
Most read on this topic
- Actual role of allogeneic haematopoietic transplantation in the treatment of acute myeloid leukaemia
- Novel molecules used in the targeted treatment of acute myeloid leukaemia – adverse reactions, treatment complications and signifi cant drug interactions
- Characteristics and results of treatment of younger patients less than 60 years old with AML: analysis of real data from the Czech DATOOL-AML database
- Effect of Azacitidine in the Treatment of Acute Myeloid Leukemia on Long-Term Patient Survival
- Oral Azacitidine Prolongs Survival of AML Patients Regardless of Measurable Residual Disease
- Current Position of Venetoclax in the Treatment of AML − Hope for a Better Prognosis?
Related topic